Imatinib resistance: diagnostic and therapeutic choices

Marianna De Muro, Odoardo Maria Olimpieri, Rosa Greco, Lidia Altomare

DOI: https://doi.org/10.7175/cmi.v4i2S.1073

Abstract

We report a case of a 42-year-old woman with t(9;22) positive chronic myeloid leukemia (CML) who developed a sub-optimal response to therapy with imatinib mesylate due to M351T mutation and low plasma level of imatinib. Dose increase of imatinib resulted in toxicity. She obtained a complete molecular response to therapy with nilotinib, without adverse events.

Keywords

Imatinib resistance; Blood level test; Nilotinib

Full Text

PDF

Statistics

Abstract: 385 views
PDF: 443 views

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.